Related Experiment Video

Updated: May 11, 2026

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice
04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

LXR agonists: new potential therapeutic drug for neurodegenerative diseases

Pei Xu1, Dabing Li, Xiaotong Tang

  • 1Department of Histology and Embryology, Third Military Medical University, Chongqing, 400038, People's Republic of China.

Molecular Neurobiology
|April 30, 2013
PubMed

Insights

Liver X receptors (LXRs) regulate lipid metabolism and inflammation in the brain. LXR agonists show therapeutic potential for neurodegenerative diseases by improving cholesterol balance and reducing neuroinflammation.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Cholesterol homeostasis defects are implicated in neurodegenerative diseases like Alzheimer's and Parkinson's.
  • Neuroinflammation, involving microglia and astrocytes, exacerbates neurodegeneration.
  • Liver X receptors (LXRs) play a crucial role in regulating lipid metabolism and inflammatory responses within the central nervous system.

Purpose of the Study:

  • To review recent advances in understanding the role of LXRs and their agonists in neurodegenerative diseases.
  • To explore the therapeutic potential of LXR agonists in managing cholesterol imbalance and neuroinflammation.

Main Methods:

  • Review of existing literature on LXR function and agonists in neurodegenerative disease models.
  • Analysis of studies investigating LXR target gene activation and its effects on cholesterol metabolism.
  • Examination of LXR agonist effects on microglial and astrocyte activation in inflammatory conditions.

Main Results:

  • LXR agonists modulate cholesterol homeostasis and attenuate neuroinflammation.
  • Studies in animal models demonstrate the efficacy of LXR agonists in various neurodegenerative conditions.
  • Development of specific, potent, and brain-penetrant LXR agonists is crucial for enhanced therapeutic outcomes.

Conclusions:

  • LXRs and their agonists represent a promising therapeutic strategy for neurodegenerative diseases.
  • Targeting LXR pathways can simultaneously address cholesterol dysregulation and neuroinflammation.
  • Further research into optimized LXR agonists may lead to improved treatments with fewer side effects.

More Related Videos

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies15:48

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

Ole Isacson: Development of New Therapies for Parkinson's Disease23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Related Concept Videos

Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Indirect-Acting Cholinergic Agonists: Pharmacological Actions01:30

Indirect-Acting Cholinergic Agonists: Pharmacological Actions

Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Long-term Potentiation01:35

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Long-term Potentiation01:25

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when presynaptic neurons...